Document Detail

Calcitriol pulse therapy and histology of parathyroid glands in hemodialysis patients.
MedLine Citation:
PMID:  14733419     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Calcitriol pulse therapy (CPT) is considered the most appropriate treatment of secondary hyperparathyroidism (sHPTH). This treatment inhibits parathyroid hormone (PTH) synthesis and secretion, suppresses parathyroid cell proliferation and controls parathyroid gland growth. However, not much is known about the effect of such therapy on parathyroid morphology. METHODS: To investigate this, we studied all first parathyroidectomies (PTx, either total or subtotal) effected in 30 hemodialysis (HD) patients referred to our surgery department by five regional dialysis units in 2000-2001. Six patients were excluded from the study because of either the persistence or the precocious relapse (in the 1st 6 months post-operation) of sHPTH. Twenty-four HD patients were considered eligible as four parathyroid glands were ablated in each patient; 96 glands were then examined histologically. The cohort consisted of 16 males and 8 females with a mean age of 54 +/- 13 SD yrs (range 20-73) and a dialysis duration of 142 +/- 71 months (range 14-289). Data concerning calcitriol treatment (doses, administration route and treatment duration) were collected for each patient. The patients were subdivided into two groups according to the treatment effected in the months preceding PTx: group A (n=13), treated by either intravenous (i.v.) (n=12) or per os (n=1) CPT, and group B (n=11), not treated at all with calcitriol or vitamin D sterols. Parathyroid gland morphology and the parenchymal cell distribution of the parathyroid glands were evaluated by a semiquantitative assessment. Serum intact PTH (iPTH), alkaline phosphatase (AP), calcium (Ca) and phosphate (P) levels were studied pre- and post-PTx. RESULTS: Chief cells (CC) were found in all glands, either alone or associated with oxyphil cells (OC). OC were present in 13 of 24 patients (54%); however, it must be underlined that they were present 12 times in group A parathyroid glands (92%), and only once in group B (9%) (p<0.01). Nodular hyperplasia was found in 71% (17/24) of patients: 92% (12/13) in group A, and 45% (5/11) in group B (p<0.05). There were no significant differences in age, gender, dialysis duration, serum levels of iPTH, AP, Ca and P levels between the two groups. CONCLUSIONS: There was a strong association between OC presence in parathyroid glands and CPT. Furthermore, nodular hyperplasia appeared to be associated significantly with CPT. There is still speculation regarding the meaning of these CPT effects on parathyroid gland histology and consequently on sHPTH pathophysiology.
Carlo Lomonte; Rocco Martino; Michele Selvaggiolo; Rosa Maria Bona; Francesco Cazzato; Rocco Milano; Giovanni Chiarulli; Carlo Basile
Related Documents :
8618199 - Steroid-resistant chronic urticaria associated with anti-thyroid microsomal antibodies ...
3304509 - Ultrasonically guided percutaneous inactivation of parathyroid tumours.
16097639 - Three basic patterns of changes in serum thyroid hormone levels in graves' disease duri...
15851359 - Use of the electrothermal vessel sealing system versus standard vessel ligation in thyr...
14967159 - Supplementation with antioxidants in the treatment of graves' disease; the effect on gl...
10668879 - Long-term results of subcutaneous parathyroid grafts in uremic patients.
3307669 - Amiodarone in the management of refractory atrial fibrillation.
16427699 - Acanthamoeba keratitis: clinical characteristics and management.
2357049 - Roux-en-y reconstruction for severe postoperative duodenogastric reflux disease.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of nephrology     Volume:  16     ISSN:  1121-8428     ISO Abbreviation:  J. Nephrol.     Publication Date:    2003 Sep-Oct
Date Detail:
Created Date:  2004-01-21     Completed Date:  2004-03-04     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9012268     Medline TA:  J Nephrol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  716-20     Citation Subset:  IM    
Department of Nephrology, Miulli Hospital, Acquaviva delle Fonti, Bari, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Calcitriol / administration & dosage*,  pharmacology
Hyperparathyroidism, Secondary / drug therapy*,  etiology,  pathology,  surgery
Middle Aged
Oxyphil Cells / pathology
Parathyroid Glands / drug effects,  pathology*
Renal Dialysis*
Retrospective Studies
Uremia / complications,  therapy
Vitamin D / analogs & derivatives,  therapeutic use
Reg. No./Substance:
1406-16-2/Vitamin D; 32222-06-3/Calcitriol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncat...
Next Document:  The protean face of renal sarcoid.